A carregar...

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study

BACKGROUND: RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall surv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Boxerman, Jerrold L., Zhang, Zheng, Safriel, Yair, Larvie, Mykol, Snyder, Bradley S., Jain, Rajan, Chi, T. Linda, Sorensen, A. Gregory, Gilbert, Mark R., Barboriak, Daniel P.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3688018/
https://ncbi.nlm.nih.gov/pubmed/23788270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!